DOCSLIB.ORG

The Two Tonditionwinkturtin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Two Tonditionwinkturtin THETWO TONDITIONWINKTURTINUS 20170232103A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2017/ 0232103 A1 Soane et al. (43 ) Pub. Date : Aug . 17, 2017 ( 54 ) EXCIPIENT COMPOUNDS FOR plication No . 62/ 245 , 513 , filed on Oct . 23, 2015 , BIOPOLYMER FORMULATIONS provisional application No . 62/ 245 ,513 , filed on Oct . (71 ) Applicant : ReForm Biologics , LLC , Cambridge , 23 , 2015 . MA (US ) Publication Classification (51 ) Int. Cl. (72 ) Inventors : David S . Soane , Palm Beach , FL (US ) ; A61K 39 /395 ( 2006 . 01 ) Philip Wuthrich , Belmont, MA (US ) ; A61K 47 / 12 (2006 . 01 ) Rosa Casado Portilla , Peabody , MA CO7K 16 /22 ( 2006 .01 ) (US ) ; Robert P . Mahoney , Newbury , A61K 47 /22 (2006 . 01 ) MA (US ) ; Mark Moody , Concord , MA CO7K 16 / 24 ( 2006 .01 ) (US ) ; Daniel G . Greene , Belmont , MA COZK 16 / 32 ( 2006 .01 ) (US ) (52 ) U . S . CI. CPC . .. A61K 39 / 39591 (2013 . 01 ) ; CO7K 16 / 241 ( 21) Appl . No. : 15 /331 , 197 ( 2013 . 01 ) ; CO7K 16 / 32 (2013 .01 ) ; CO7K 16 / 22 ( 2013 . 01 ) ; A61K 47/ 48215 ( 2013 .01 ) ; A61K (22 ) Filed : Oct . 21 , 2016 47 / 22 ( 2013 . 01 ) ; A61K 47 / 12 ( 2013 . 01) ; COZK 2317 /21 ( 2013 .01 ) ; CO7K 2317 /24 (2013 .01 ) Related U . S . Application Data ( 57 ) ABSTRACT (63 ) Continuation - in -part of application No . 14 / 966 ,549 , The invention encompasses formulations and methods for filed on Dec. 11 , 2015 , now Pat . No . 9 ,605 , 051 , which the production thereof that permit the delivery of concen is a continuation of application No . 14 /744 , 847 , filed trated protein solutions. The inventive methods can yield a on Jun . 19 , 2015 . lower viscosity liquid protein formulation or a higher con (60 ) Provisional application No. 62 /014 ,784 , filed on Jun . centration of therapeutic or nontherapeutic proteins in the 20 , 2014 , provisional application No. 62 /083 ,623 , liquid formulation , as compared to traditional protein solu filed on Nov . 24 , 2014 , provisional application No. tions . The inventive methods can also yield a higher stability 62 / 136 , 763 , filed on Mar. 23 , 2015 , provisional ap of a liquid protein formulation . Patent Application Publication Aug. 17, 2017 Sheet10f 3 US2017 / 0232103A1 $ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? . ? ' ? ? . ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? . .' . ? . ? . ? ? . ? ? ? . $3 ?? . ? ? ? ? ? ? ? ? ? ? . ; . ? ? ? . ? ? ? . ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 8 Sample 1 - FT ; ?? ? ? ? . ? ? ? ?? ? ? ? ? ? ? ?? ?? ?? ?? ?? ? ? ? ? ? ? ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? . ? ? ? ? ? 65883934144 ? ? ? ? ? ? ? ? ? ? ? ? 7? ? Sample 1 - A ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? . 3_8 ? ? ? ? ? ? ? ? ? ? ? ? ? ? a m bie } } ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ??? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?? .???????? ? ? ? ?? ? ? ? ? ? ?? ? ? ? ? ? ? ? ? ? ?? ? ? ? ? ? ??? plam???Y {nm FIG, 1 Patent Application Publication Aug. 17, 2017 Sheet 2 0f 3 US2017 / 0232103A1 $ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? . ? ? ? ? ? ? ? ? ? ? . ? ? ? ? ? ? . ? ? ? ? ? ? ? ? ? ? . ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? . ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? Sample 2- FT ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?? . ? 4435448824? 3 ? ? ? ? ? ? ? . ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?? ? ? ? ? ? ? ? ? ? ? XX5888 3 ? ? ? ? ? ? ?? ? ? ?? ? .? ?Sarmpie 2: 8 ? ?? ?? ? ? ?? ?? ? ?? ?? ?? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? . ? ? . ? ? ? ? . ? ? ? ? . ? ? . - w " ? ? ? ?? ? . ? ?? ? ? ? . ? . ?? ? ? ?? ? * * * . ? ? * ? . ? ? ? ? ? ? ? ? ? ? . ? . ? ? ? ? ? ? ? ? ? ? ? ? ? 3?? ? ? ? ? ?? ?? ? ? ?? ? ?? ?? . ? ? Sample 2 -6 ? ? ?? ?? ?? ?? ?? ? ? ?? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?? ? ?. ?. .. ? .. .? ? ???????. .?? ???????????????????????????????????????????? Diameter (nm ) FIG . 2 Patent Application Publication Aug. 17 , 2017 Sheet 3 of 3 US 2017 /0232103 A1 * * * . .* . * . * .* . * . * . * .* . * . * .* . * . * . * .* . * . * .* . * . * . * .* . * . * .* . * . * . *. * . * . * .* . * . * . *. * . * . * .* . * . * . *. * . * . * .* . * . * . * .* . * . * .* . * . * . *. * . * . * .* . * . * . *. * . * . * .* . * . * . *. * . * . * .* . * . * . *. * . * . * . * . * . *. * . * . * .* . * . * . *. * . * . * . * . * . * . * . * . * . * . * . * . * . 44.71 . Sample 2 - 0 . 7 . *+ .- . Sample 2 - A . * . * . wwww *. .. * . BV ** . * * * * ! Sample 2 -FT . *.173 *** ** . A.U minim i zimin os .. .. .. .. .. .. .. .. .. .. .. .. .. .. 6 8 10 121 Time (min ) FIG . 3 US 2017 /0232103 A1 Aug . 17 , 2017 EXCIPIENT COMPOUNDS FOR [ 0007 ] As an example , one approach to producing protein BIOPOLYMER FORMULATIONS formulations for injection is to transform the therapeutic protein solution into a powder that can be reconstituted to RELATED APPLICATIONS form a suspension suitable for SC or IM delivery . [0001 ] This application is a continuation - in - part of U . S . Lyophilization is a standard technique to produce protein application Ser . No. 14 / 966 , 549 filed Dec . 11 , 2015 which is powders . Freeze - drying , spray drying and even precipitation a continuation of U . S . application Ser. No . 14 /744 ,847 filed followed by super - critical - fluid extraction have been used to Jun . 19 , 2015 which claims the benefit of U . S . Provisional generate protein powders for subsequent reconstitution . Application No . 62 /014 ,784 filed Jun . 20 , 2014 , U . S . Pro Powdered suspensions are low in viscosity before re -disso visional Application No. 62 /083 ,623 , filed Nov . 24 , 2014 , lution ( compared to solutions at the same overall dose ) and and U . S . Provisional Application Ser . No . 62 / 136 , 763 filed thus may be suitable for SC or IM injection , provided the Mar . 23 , 2015 ; U . S . application Ser . No. 14 / 966 ,549 also particles are sufficiently small to fit through the needle . claims the benefit of U . S . Provisional Application No. However, protein crystals that are present in the powder 62/ 245 ,513 , filed Oct . 23 , 2015 ; this application also claims have the inherent risk of triggering immune response. The the benefit of U . S . Provisional Application No . 62 / 245 , 513 , uncertain protein stability / activity following re - dissolution filed Oct . 23 , 2015 . The entire contents of the each of the poses further concerns . There remains a need in the art for above applications are incorporated by reference herein . techniques to produce low viscosity protein formulations for therapeutic purposes while avoiding the limitations intro FIELD OF APPLICATION duced by protein powder suspensions. [ 0002 ] This application relates generally to formulations 10008 ] In addition to the therapeutic applications of pro for delivering biopolymers. teins described above , biopolymers such as enzymes , pep tides , and structural proteins can be used in non - therapeutic applications . These non - therapeutic biopolymers can be BACKGROUND produced from a number of different pathways, for example , [ 0003] Biopolymers may be used for therapeutic or non derived from plant sources , animal sources , or produced therapeutic purposes . Biopolymer -based therapeutics, such from cell cultures . as antibody or enzyme formulations , are widely used in [ 0009 ] The non - therapeutic proteins can be produced , treating disease . Non - therapeutic biopolymers , such as transported , stored , and handled as a granular or powdered enzymes , peptides, and structural proteins , have utility in material or as a solution or dispersion , usually in water . The non - therapeutic applications such as household , nutrition , biopolymers for non - therapeutic applications can be globu commercial , and industrial uses. lar or fibrous proteins , and certain forms of these materials [ 0004 ] Biopolymers used in therapeutic applications must can have limited solubility in water or exhibit high viscosity be formulated to permit their introduction into the body for upon dissolution . These solution properties can present treatment of disease . For example , it is advantageous to challenges to the formulation , handling , storage, pumping , deliver antibody and protein /peptide biopolymer formula and performance of the non - therapeutic materials , so there is tions by subcutaneous (SC ) or intramuscular ( IM ) routes a need for methods to reduce viscosity and improve solu under certain circumstances , instead of administering these bility and stability of non - therapeutic protein solutions . formulations by intravenous ( IV ) injections. In order to achieve better patient compliance and comfort with SC or [0010 ] Proteins are complex biopolymers, each with a IM injection though , the liquid volume in the syringe is uniquely folded 3 - D structure and surface energy map typically limited to 2 to 3 ccs and the viscosity of the (hydrophobic / hydrophilic regions and charges ). In concen formulation is typically lower than about 20 centipoise ( CP ) trated protein solutions , these macromolecules may strongly so that the formulation can be delivered using conventional interact and even inter - lock in complicated ways , depending medical devices and small -bore needles.
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.468,645 B2 Owoc (45) Date of Patent: Oct
    USOO9468645B2 (12) United States Patent (10) Patent No.: US 9.468,645 B2 OWOc (45) Date of Patent: Oct. 18, 2016 (54) HIGHLY SOLUBLE PURINE BOACTIVE (2013.01); A61K 9/0019 (2013.01); A61 K COMPOUNDS AND COMPOSITIONS 9/0095 (2013.01); A61K 9/4858 (2013.01); THEREOF A61 K3I/00 (2013.01); A61K 45/06 (2013.01); A23 V 2002/00 (2013.01) (71) Applicant: JHO Intellectual Property Holdings, (58) Field of Classification Search LLC, Davie, FL (US) CPC ..................... A23V 2002/00; A23V 2200/31; (72) Inventor: Jack Owoc, Weston, FL (US) A23V 2250/062: A23V 2250/21: A23V 2250/5108: A23V 2250/5118: A23V (*) Notice: Subject to any disclaimer, the term of this 2250/54246; A23V 2250/54252: A23V patent is extended or adjusted under 35 2250/704; A23V 2250/712: A61K 31/522; U.S.C. 154(b) by 3 days. A61K 2300/00; A61K 45/06; A61 K9/00 See application file for complete search history. (21) Appl. No.: 14/628,626 (56) References Cited (22) Filed: Feb. 23, 2015 U.S. PATENT DOCUMENTS (65) Prior Publication Data 837,282 A * 12/1906 Owoc ....................... EO1B 9/60 US 2015/O238494 A1 Aug. 27, 2015 238,292 5,973,005 A * 10/1999 D'Amelio, Sr. ... CO7C 277/08 514,565 Related U.S. Application Data 2006/0236421 A1* 10, 2006 Pennell ................ C12N 9/1007 800,278 (60) Provisional application No. 61/944,528, filed on Feb. 2009,0257997 A1* 10, 2009 Owoc .................. A61K9/0014 25, 2014. 424/94.1 (51) Int. C. * cited by examiner A6 IK3I/522 (2006.01) A6 IK 45/06 (2006.01) Primary Examiner – Debbie K Ware A2.3L 2/52 (2006.01) (74) Attorney, Agent, or Firm — David W.
    [Show full text]
  • Identification and Characterization of N 9-Methyltransferase Involved In
    ARTICLE https://doi.org/10.1038/s41467-020-15324-7 OPEN Identification and characterization of N9- methyltransferase involved in converting caffeine into non-stimulatory theacrine in tea Yue-Hong Zhang1,2,3,6, Yi-Fang Li1,2,3,6, Yongjin Wang1,3,6, Li Tan1,3, Zhi-Qin Cao1,2,3, Chao Xie1,2,3, Guo Xie4, Hai-Biao Gong1,2,3, Wan-Yang Sun1,2,3, Shu-Hua Ouyang1,2,3, Wen-Jun Duan1,2,3, Xiaoyun Lu1,3, Ke Ding 1,3, ✉ ✉ ✉ ✉ Hiroshi Kurihara1,2,3, Dan Hu 1,2,3 , Zhi-Min Zhang 1,3 , Ikuro Abe 5 & Rong-Rong He 1,2,3 1234567890():,; Caffeine is a major component of xanthine alkaloids and commonly consumed in many popular beverages. Due to its occasional side effects, reduction of caffeine in a natural way is of great importance and economic significance. Recent studies reveal that caffeine can be converted into non-stimulatory theacrine in the rare tea plant Camellia assamica var. kucha (Kucha), which involves oxidation at the C8 and methylation at the N9 positions of caffeine. However, the underlying molecular mechanism remains unclear. Here, we identify the theacrine synthase CkTcS from Kucha, which possesses novel N9-methyltransferase activity using 1,3,7-trimethyluric acid but not caffeine as a substrate, confirming that C8 oxidation takes place prior to N9-methylation. The crystal structure of the CkTcS complex reveals the key residues that are required for the N9-methylation, providing insights into how caffeine N-methyltransferases in tea plants have evolved to catalyze regioselective N-methylation through fine tuning of their active sites.
    [Show full text]
  • Pharmacokinetics of Caffeine: a Systematic Analysis of Reported Data
    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.12.452094; this version posted August 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Pharmacokinetics of caffeine: A systematic analysis of reported data for application in metabolic phenotyping and liver function testing Jan Grzegorzewski 1, Florian Bartsch 1, Adrian Koller¨ 1, and Matthias Konig¨ 1;∗ 1Institute for Theoretical Biology, Humboldt-University Berlin, Invalidenstraße 110, 10115 Berlin, Germany Correspondence*: Matthias Konig¨ [email protected] ABSTRACT Caffeine is by far the most ubiquitous psychostimulant worldwide found in tea, coffee, cocoa, energy drinks, and many other beverages and food. Caffeine is almost exclusively metabolized in the liver by the cytochrome P-450 enzyme system to the main product paraxanthine and the additional products theobromine and theophylline. Besides its stimulating properties, two important applications of caffeine are metabolic phenotyping of cytochrome P450 1A2 (CYP1A2) and liver function testing. An open challenge in this context is to identify underlying causes of the large inter-individual variability in caffeine pharmacokinetics. Data is urgently needed to understand and quantify confounding factors such as lifestyle (e.g. smoking), the effects of drug-caffeine interactions (e.g. medication metabolized via CYP1A2), and the effect of disease. Here we report the first integrative and systematic analysis of data on caffeine pharmacokinetics from 148 publications and provide a comprehensive high-quality data set on the pharmacokinetics of caffeine, caffeine metabolites, and their metabolic ratios in human adults. The data set is enriched by meta-data on the characteristics of studied patient cohorts and subjects (e.g.
    [Show full text]
  • Caffeine and Chlorogenic Acid Contents Among Wild Coffea
    Food Chemistry Food Chemistry 93 (2005) 135–139 www.elsevier.com/locate/foodchem Qualitative relationship between caffeine and chlorogenic acid contents among wild Coffea species C. Campa, S. Doulbeau, S. Dussert, S. Hamon, M. Noirot * Centre IRD of Montpellier, B.P. 64501, 34394 Montpellier Cedex 5, France Received 28 June 2004; received in revised form 13 October 2004; accepted 13 October 2004 Abstract Chlorogenic acids, sensu largo (CGA), are secondary metabolites of great economic importance in coffee: their accumulation in green beans contributes to coffee drink bitterness. Previous evaluations have already focussed on wild species of coffee trees, but this assessment included six new taxa from Cameroon and Congo and involved a simplified method that generated more accurate results. Five main results were obtained: (1) Cameroon and Congo were found to be a centre of diversity, encompassing the entire range of CGA content from 0.8% to 11.9% dry matter basis (dmb); (2) three groups of coffee tree species – CGA1, CGA2 and CGA3 – were established on the basis of discontinuities; (3) means were 1.4%, 5.6% and 9.9% dmb, respectively; (4) there was a qualitative relation- ship between caffeine and ACG content distribution; (5) only a small part of the CGA is trapped by caffeine as caffeine chlorogenate. Ó 2004 Elsevier Ltd. All rights reserved. Keywords: Coffeae; Caffeine; Chlorogenic acids 1. Introduction lic acid [feruloylquinic acids (FQA)] and represent 98% of all CGAs (Clifford, 1985; Morishita, Iwahashi, & Two coffee species, C. canephora and C. arabica, are Kido, 1989). There are also some minor compounds, cultivated worldwide. However, these species only repre- such as esters of feruloyl-caffeoylquinic acids (FCQA), sent a small proportion of the worldÕs coffee genetic re- caffeoyl-feruloylquinic acids (CFQA) or p-coumaric acid sources as, in the wild, the Coffea subgenus (Coffea (p-CoQA).
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Theacrine Attenuates Myocardial Fibrosis After Myocardial Infarction Via the SIRT3/Β-Catenin/ Pparγ Pathway in Estrogen-Deficient Mice
    European Review for Medical and Pharmacological Sciences 2019; 23: 5477-5486 Theacrine attenuates myocardial fibrosis after myocardial infarction via the SIRT3/β-catenin/ PPARγ pathway in estrogen-deficient mice L.-L. SONG1, Y. ZHANG2, X.-R. ZHANG3, Y.-N. SONG4, H.-Z. DAI5 1Department of Critical Care Medicine, Weifang Hanting District People’s Hospital, Weifang, China 2Department of Respiratory Medicine, Weifang Hanting District People’s Hospital, Weifang, China 3Department of Pharmacology, Weifang Medical University, Weifang, China 4Department of Breast and Thyroid Surgery, The Traditional Chinese Medicine Hospital of Weifang, Weifang, China 5Department of Emergency, The Affiliated Hospital of Weifang Medical University, Weifang, China Abstract. – OBJECTIVE: To investigate the myocardial apoptosis were clearly aggravated, role of theacrine in the protection of ventricular and the SIRT3 expression was decreased at 28 remodeling and chronic heart failure after myo- days after myocardial infarction. The theacrine cardial infarction in the estrogen-deficient mice. could improve the cardiac function after the MATERIALS AND METHODS: Female myocardial infarction in estrogen-deficient mice C57BL/6 mice aged 8 weeks old were selected and relieve both myocardial fibrosis and myo- and then subjected to bilateral oophorectomy. cardial apoptosis during chronic remodeling af- At 7 days after surgery, the models of the myo- ter myocardial infarction in estrogen-deficient cardial infarction were established by ligating mice. After the intervention with theacrine, the the anterior descending coronary artery. On the estrogen-deficient mice with myocardial infarc- first day after myocardial infarction, Theacrine tion had up-regulated SIRT3 and PPARγ levels (20 mg/kg) was administered via gavage for con- and a reduced β-catenin level in the heart.
    [Show full text]
  • Herbal Principles in Cosmetics Properties and Mechanisms of Action Traditional Herbal Medicines for Modern Times
    Traditional Herbal Medicines for Modern Times Herbal Principles in Cosmetics Properties and Mechanisms of Action Traditional Herbal Medicines for Modern Times Each volume in this series provides academia, health sciences, and the herbal medicines industry with in-depth coverage of the herbal remedies for infectious diseases, certain medical conditions, or the plant medicines of a particular country. Series Editor: Dr. Roland Hardman Volume 1 Shengmai San, edited by Kam-Ming Ko Volume 2 Rasayana: Ayurvedic Herbs for Rejuvenation and Longevity, by H.S. Puri Volume 3 Sho-Saiko-To: (Xiao-Chai-Hu-Tang) Scientific Evaluation and Clinical Applications, by Yukio Ogihara and Masaki Aburada Volume 4 Traditional Medicinal Plants and Malaria, edited by Merlin Willcox, Gerard Bodeker, and Philippe Rasoanaivo Volume 5 Juzen-taiho-to (Shi-Quan-Da-Bu-Tang): Scientific Evaluation and Clinical Applications, edited by Haruki Yamada and Ikuo Saiki Volume 6 Traditional Medicines for Modern Times: Antidiabetic Plants, edited by Amala Soumyanath Volume 7 Bupleurum Species: Scientific Evaluation and Clinical Applications, edited by Sheng-Li Pan Traditional Herbal Medicines for Modern Times Herbal Principles in Cosmetics Properties and Mechanisms of Action Bruno Burlando, Luisella Verotta, Laura Cornara, and Elisa Bottini-Massa Cover art design by Carlo Del Vecchio. CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2010 by Taylor and Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-13: 978-1-4398-1214-3 (Ebook-PDF) This book contains information obtained from authentic and highly regarded sources.
    [Show full text]
  • The Two Tortoitumia Ultimate Tatli Himin
    THETWO TORTOITUMIAUS 20180104248A1ULTIMATE TATLI HIMIN ( 19) United States ( 12) Patent Application Publication ( 10 ) Pub . No. : US 2018 /0104248 A1 Lopez et al. (43 ) Pub . Date : Apr . 19 , 2018 ( 54 ) THEACRINE -BASED SUPPLEMENT AND Publication Classification METHOD OF USE THEREOF IN A (51 ) Int. Cl. SYNERGISTIC COMBINATION WITH A61K 31/ 522 ( 2006 . 01 ) CAFFEINE C07D 487/ 04 (2006 . 01) (52 ) U . S . CI. @( 71 ) Applicant : Ortho - Nutra, LLC , Morganville , NJ CPC .. A61K 31/ 522 ( 2013 .01 ) ; C07D 487 /04 (US ) ( 2013. 01 ) @(72 ) Inventors : Hector L Lopez , Cream Ridge , NJ (US ) ; Shawn Wells , Lewisville , TX (US ) ; Tim N . Ziegenfuss , Chardon , OH (57 ) ABSTRACT (US ) A human dietary supplement comprises theacrine and @( 73 ) Assignee : Ortho -Nutra , LLC , Morganville , NJ optionally other compounds that modulate the effects of theacrine . Uses for the theacrine - containing supplement (US ) include improvement of at least one ofmood , energy, focus, concentration or sexual desire or a reduction of at least one (21 ) Appl. No. : 15 /600 , 371 of anxiety or fatigue. A synergistic composition comprises ( 22 ) Filed : May 19 , 2017 co -administration of theacrine and caffeine , wherein the co - administered caffeine reduces theacrine oral clearance Related U . S . Application Data (CL / F ) and oral volume of distribution (Vd / F ) . In addition , the co - administered caffeine increases area under the plasma (63 ) Continuation - in -part of application No. 14 / 539, 726 , concentration time curve ( AUC ) of theacrine , and increases filed on Nov. 12 , 2014 . theacrine maximum plasma concentration ( Cmax ) in com (60 ) Provisional application No .61 / 903 ,362 , filed on Nov . parison with the corresponding pharmacokinetic parameters 12 , 2013 .
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction
    pharmaceutics Review Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction Maria D. Auxtero 1, Susana Chalante 1,Mário R. Abade 1 , Rui Jorge 1,2,3 and Ana I. Fernandes 1,* 1 CiiEM, Interdisciplinary Research Centre Egas Moniz, Instituto Universitário Egas Moniz, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal; [email protected] (M.D.A.); [email protected] (S.C.); [email protected] (M.R.A.); [email protected] (R.J.) 2 Polytechnic Institute of Santarém, School of Agriculture, Quinta do Galinheiro, 2001-904 Santarém, Portugal 3 CIEQV, Life Quality Research Centre, IPSantarém/IPLeiria, Avenida Dr. Mário Soares, 110, 2040-413 Rio Maior, Portugal * Correspondence: [email protected]; Tel.: +35-12-1294-6823 Abstract: Late-life mild cognitive impairment and dementia represent a significant burden on health- care systems and a unique challenge to medicine due to the currently limited treatment options. Plant phytochemicals have been considered in alternative, or complementary, prevention and treat- ment strategies. Herbals are consumed as such, or as food supplements, whose consumption has recently increased. However, these products are not exempt from adverse effects and pharmaco- logical interactions, presenting a special risk in aged, polymedicated individuals. Understanding pharmacokinetic and pharmacodynamic interactions is warranted to avoid undesirable adverse drug reactions, which may result in unwanted side-effects or therapeutic failure. The present study reviews the potential interactions between selected bioactive compounds (170) used by seniors for cognitive enhancement and representative drugs of 10 pharmacotherapeutic classes commonly prescribed to the middle-aged adults, often multimorbid and polymedicated, to anticipate and prevent risks arising from their co-administration.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]